NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Parabilis Medicines PBLS

Parabilis Medicines listed on Nasdaq on 10 Jun 2026 and is not in the S&P 500. It is worth $3.5 billion. Its price history starts on 12 Jun 2026. 11 directors have filed with the SEC in the last 12 months (who counts), 1 of them an executive. 5 other officers are on file. At 30 Jun 2026, Ra Capital Management was its largest institutional holder, with 23.4% of the company.

CEO
Mathai Mammen
Listed
10 Jun 2026 on Nasdaq, IPO filings and terms
Headquarters
Cambridge, MA
Market cap
$3.5B
19 Nov 2026 close
Revenue
-
No annual report yet

Financials

Financial history

Twelve months to 30 Sep 2026, from Parabilis Medicines's quarterly filings.

Quarters since Jun 2026

P/E
-
No profit over the last four quarters

Quarterly results

Each quarter's revenue, net income and free cash flow.

Jun 2026 to Sep 2026

Not reported for enough quarters.

Parabilis Medicines's market cap since June 2026

Weekly, up to 13 Nov 2026

Jul 2026AugSepOctNov$3.6B

Board and leadership

Board and officers

Roles filed up to 30 Sep 2026

NameTitle
Directors (11)
Mathai MammenPresident & CEOPresident & CEO
Alexis BorisyDirectorDirector
Edward M. FitzgeraldDirectorDirector
Richard KlausnerDirectorDirector
Peter KolchinskyDirectorDirector
Alan SebulskyDirectorDirector
Rajeev M. ShahDirectorDirector
Jake SimsonDirectorDirector
Craig TendlerDirectorDirector
Barbara WeberDirectorDirector
Krishna YeshwantDirectorDirector
Officers (5)
Thomas Rodolpho KotarakosChief Financial OfficerLast filed 9 Jun 2026Chief Financial Officer
Mohammed Fawzi BenzaghouChief Medical OfficerLast filed 9 Jun 2026Chief Medical Officer
Helen Huei-in HoChief Business and Strategy OfficerLast filed 9 Jun 2026Chief Business and Strategy Officer
Teresa JurgensenGeneral CounselLast filed 9 Jun 2026General Counsel
Rohin MhatreChief Technical Operations OfficerLast filed 9 Jun 2026Chief Technical Operations Officer

Owners and trading

Largest institutional holders

Each fund group's share of Parabilis Medicines. Where a company has several share classes, the share is of its total value.

13F filings for the quarter to 30 Jun 2026

  • Ra Capital Management23.4%
  • Fidelity (FMR)8.3%
  • Arch Venture Management5.2%
  • venBio Partners4.3%
  • Alphabet4.0%

These five hold 45.2% of Parabilis Medicines.

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers made no open-market sales and bought $431 million in 7 purchases in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
22 Jul 2026BuyPeter KolchinskyDirectorDirectorBuy47,250$1.4M
21 Jul 2026BuyPeter KolchinskyDirectorDirectorBuy65,923$1.9M
20 Jul 2026BuyPeter KolchinskyDirectorDirectorBuy131,420$3.6M
15 Jun 2026BuyAlan SebulskyDirectorDirectorBuy9,065$240K
12 Jun 2026BuyAlan SebulskyDirectorDirectorBuy8,435$233K
11 Jun 2026BuyPeter KolchinskyDirectorDirectorBuy21,188,750$424M
11 Jun 2026BuyAlan SebulskyDirectorDirectorBuy12,500$250K

Timeline

Leadership changes, layoffs and insider sales

20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025

1 departure and 1 appointment of directors and officers in the last two years.

Left the company or board 1Appointed 1WARN layoff notices 0Large insider sales 0Jan 2025AprJulOctJan 2026AprJulOct

Events, newest first

Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet and no earnings release figures from the last six months.